Oncology Central

Clinical players and healthcare payers: aligning perspectives on the cost–effectiveness of next-generation sequencing in oncology


Recent discussion surrounding the clinical implementation of genome sequencing has touted its cost–effectiveness [1]. However, the simplistic assumption that lowering the cost of next-generation sequencing (NGS) testing equates to cost–effectiveness is misguided and lacks evidence. Wide spread NGS testing in oncology will incur large upfront screening costs; potentially with no impact on treatment outcomes. In those instances where valuable information is revealed the use of an expensive targeted therapy is likely to be indicated. Therefore, it is essential to have reliable clinical and economic evidence supporting the clinical implementation of tumor-focused NGS testing. Inappropriate use could result in inefficiencies; reducing societies’ ability to provide (quality) healthcare to others.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.